Exome Asset Management as of Dec. 31, 2024
Portfolio Holdings for Exome Asset Management
Exome Asset Management holds 59 positions in its portfolio as reported in the December 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Bridgebio Pharma (BBIO) | 5.1 | $6.8M | 247k | 27.44 | |
| Eli Lilly & Co. (LLY) | 4.8 | $6.4M | 8.2k | 772.00 | |
| Geron Corporation (GERN) | 4.2 | $5.6M | 1.6M | 3.60 | |
| Humana (HUM) | 3.4 | $4.6M | 18k | 253.71 | |
| Guardant Health (GH) | 3.4 | $4.5M | 148k | 30.55 | |
| Relay Therapeutics (RLAY) | 3.4 | $4.5M | 1.1M | 4.12 | |
| Disc Medicine (IRON) | 3.3 | $4.4M | 69k | 63.40 | |
| Syndax Pharmaceuticals (SNDX) | 3.2 | $4.2M | 319k | 13.22 | |
| Arvinas Ord (ARVN) | 3.1 | $4.2M | 219k | 19.17 | |
| Structure Therapeutics Sponsored Ads (GPCR) | 3.1 | $4.1M | 152k | 27.12 | |
| Intuitive Surgical Com New (ISRG) | 2.9 | $3.9M | 7.4k | 521.96 | |
| Apellis Pharmaceuticals (APLS) | 2.9 | $3.8M | 120k | 31.91 | |
| Bristol Myers Squibb (BMY) | 2.8 | $3.7M | 65k | 56.56 | |
| Boston Scientific Corporation (BSX) | 2.7 | $3.6M | 41k | 89.32 | |
| Natera (NTRA) | 2.7 | $3.6M | 23k | 158.30 | |
| Soleno Therapeutics (SLNO) | 2.6 | $3.5M | 77k | 44.95 | |
| Scholar Rock Hldg Corp (SRRK) | 2.5 | $3.3M | 77k | 43.22 | |
| Nuvalent Inc-a (NUVL) | 2.4 | $3.2M | 41k | 78.51 | |
| Cytokinetics Com New (CYTK) | 2.3 | $3.1M | 66k | 47.04 | |
| Blueprint Medicines (BPMC) | 2.1 | $2.8M | 32k | 87.22 | |
| Gilead Sciences (GILD) | 2.1 | $2.7M | 30k | 92.37 | |
| Summit Therapeutics (SMMT) | 1.7 | $2.3M | 130k | 17.84 | |
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 1.7 | $2.3M | 138k | 16.75 | |
| Edgewise Therapeutics (EWTX) | 1.6 | $2.2M | 82k | 26.70 | |
| Janux Therapeutics (JANX) | 1.6 | $2.1M | 40k | 53.54 | |
| Savara (SVRA) | 1.6 | $2.1M | 700k | 3.07 | |
| Ionis Pharmaceuticals (IONS) | 1.6 | $2.1M | 61k | 34.96 | |
| Penumbra (PEN) | 1.6 | $2.1M | 9.0k | 237.48 | |
| Rocket Pharmaceuticals (RCKT) | 1.5 | $2.0M | 160k | 12.57 | |
| Akero Therapeutics (AKRO) | 1.4 | $1.9M | 69k | 27.82 | |
| Dr Reddys Labs Adr (RDY) | 1.4 | $1.9M | 118k | 15.79 | |
| Beigene Sponsored Adr (ONC) | 1.4 | $1.8M | 10k | 184.71 | |
| 89bio (ETNB) | 1.3 | $1.8M | 225k | 7.82 | |
| Tarsus Pharmaceuticals (TARS) | 1.2 | $1.6M | 28k | 55.37 | |
| Karyopharm Therapeutics Note 3.000%10/1 | 1.2 | $1.6M | 2.0M | 0.78 | |
| Pliant Therapeutics (PLRX) | 1.0 | $1.4M | 104k | 13.17 | |
| Fulcrum Therapeutics (FULC) | 1.0 | $1.3M | 284k | 4.70 | |
| Stoke Therapeutics (STOK) | 0.9 | $1.2M | 113k | 11.03 | |
| Legend Biotech Corp Sponsored Ads (LEGN) | 0.9 | $1.2M | 38k | 32.54 | |
| Tectonic Therapeutic (TECX) | 0.9 | $1.2M | 26k | 46.17 | |
| Alvotech Ordinary Shares (ALVO) | 0.9 | $1.2M | 90k | 13.23 | |
| Vyne Therapeutics (VYNE) | 0.9 | $1.2M | 353k | 3.35 | |
| Eledon Pharmaceuticals (ELDN) | 0.8 | $1.1M | 256k | 4.12 | |
| Biohaven (BHVN) | 0.8 | $1.1M | 28k | 37.35 | |
| Gossamer Bio (GOSS) | 0.7 | $993k | 1.1M | 0.90 | |
| Aclaris Therapeutics (ACRS) | 0.7 | $966k | 389k | 2.48 | |
| Annexon (ANNX) | 0.6 | $743k | 145k | 5.13 | |
| Female Health (VERU) | 0.6 | $740k | 1.1M | 0.66 | |
| Acelyrin | 0.6 | $736k | 234k | 3.14 | |
| Replimune Group (REPL) | 0.5 | $663k | 55k | 12.11 | |
| Establishment Labs Holdings Ord (ESTA) | 0.5 | $604k | 13k | 46.07 | |
| Nektar Therapeutics | 0.4 | $575k | 618k | 0.93 | |
| Aprea Therapeutics Com New (APRE) | 0.3 | $420k | 128k | 3.28 | |
| Akebia Therapeutics (AKBA) | 0.3 | $391k | 206k | 1.90 | |
| Madrigal Pharmaceuticals (MDGL) | 0.2 | $305k | 987.00 | 308.57 | |
| Leap Therapeutics Com New (LPTX) | 0.2 | $295k | 103k | 2.88 | |
| Mersana Therapeutics | 0.2 | $250k | 173k | 1.44 | |
| Neumora Therapeutics Call Call Option | 0.2 | $207k | 600.00 | 345.00 | |
| Arbutus Biopharma (ABUS) | 0.1 | $93k | 28k | 3.27 |
